News

Two Additional Organic Compliance Listings Obtained for AgroSpheres Novel Encapsulation Platform for Use in Organic Crop Production

AgroSpheres, Inc., an agricultural biobased solutions developer, recently received certificates attesting to the organic input compliance of its proprietary encapsulation technology, AgroSpheres® Microbially-Derived Minicells (also known as the AgriCell), and its formulated encapsulated thyme oil product, Thyme Oil 26% LC Biofungicide from the Organic Materials Review Institute (OMRI). OMRI, the leading certifier of organic inputs for agriculture, has determined that both products meet the criteria for use under the USDA National Organic Program (NOP).

AgroSpheres® Microbially-Derived Minicells is now listed in OMRI’s Generic Material Listing for use as (1) an inert ingredient in organic crop pest, weed, and disease control and (2) as an adjuvant for use in fertilizers and soil amendments in crop management tools and production aids.

Thyme Oil 26% LC Biofungicide is now listed by OMRI as a biopesticide for use in crop pest, weed, and disease control.

AgroSpheres® Microbially-Derived Minicells may be used as an adjuvant in fertilizers and soil amendments beginning immediately.

However, for crop pest, weed, and disease control uses, please note that both AgroSpheres® Microbially-Derived Minicells and Thyme Oil 26% LC Biofungicide are currently pending review and approval by US EPA. Once those approvals are granted, they will be available for use in organic and conventional crop production.

These certificates symbolize that these AgroSpheres’ products meet the stringent criteria NOP has created for the organic industry. This significant milestone marks a major step forward in advancing environmentally friendly and efficient agricultural practices.

“We are extremely pleased to have received this acknowledgement from OMRI. This certification opens up our ability to sell to all growers and provide tools for organic growers that are in desperate need. In our previous year of field trials, our Thyme Oil 26% product performed very well against both OMRI and conventional products,” said Reese Blackwell, Chief Business Officer for AgroSpheres.

In recent field trials, growers have not only seen great product efficacy but also added plant health benefits of this OMRI product. Below are a couple of the grower remarks that AgroSpheres received in last season’s trial program.

  • “You could notice a difference in the crop between treatments. When we dropped the crop to the ground in the AgroSpheres treatment area, the overall crop quality looked better vs. the other treatments in the field.” – Grape Grower (Sacramento, CA)
  • “Overall plant health looks better in the AgroSpheres treatment vs. the untreated control, and the competitive product.” – Almond Grower (Crows Landing, CA)

The encapsulated products will be sold through various distributors after product approvals.

To see a complete list of the OMRI Listed® certificates for AgroSpheres® products, click here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and